Department of Nephrology, SBU. Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.
Department of Nephrology, Acıbadem Hospital, Bursa, Turkey.
Ther Apher Dial. 2023 Jun;27(3):402-411. doi: 10.1111/1744-9987.13930. Epub 2022 Oct 6.
This study aimed to compare the infection rate and infection-related mortality among all renal replacement therapies during the COVID-19 pandemics.
One thousand three hundred thirty-six end-stage renal disease (ESRD) patients who had applied for renal replacement therapy between March 2020 and January 2021 were included in the study. COVID-19 infection and mortality rates were compared between patient groups.
The COVID-19 infection rate in the whole study group was 13.12% (n: 178). The highest infection rate was in the center hemodialysis, 16.33% (n: 139). There was no COVID-19 infection in home hemodialysis (HHD). Mortality rate was 2.87% (n: 39) in the whole cohort and 3.87% (n: 33) in center hemodialysis (CHD), 1.47% (n:5) in kidney transplant (Tx), and 0.81% (n: 1) in the peritoneal dialysis (PD) group. COVID-19 infection rate of home replacement therapy (HRT) (n: 39) patients was significantly lower than CHD (n: 139) (p < 0.001).
The COVID-19 infection rate and mortality were significantly lower than those of CHD in all home-based modalities subgroups.
本研究旨在比较 COVID-19 大流行期间所有肾脏替代疗法的感染率和与感染相关的死亡率。
纳入了 2020 年 3 月至 2021 年 1 月期间申请肾脏替代治疗的 1336 名终末期肾病（ESRD）患者。比较了患者组之间的 COVID-19 感染率和死亡率。
全组 COVID-19 感染率为 13.12%（n：178）。中心血液透析组的感染率最高，为 16.33%（n：139）。家庭血液透析（HHD）组无 COVID-19 感染。全队列的死亡率为 2.87%（n：39），中心血液透析组（CHD）为 3.87%（n：33），肾移植（Tx）组为 1.47%（n：5），腹膜透析（PD）组为 0.81%（n：1）。家庭替代治疗（HRT）（n：39）患者的 COVID-19 感染率明显低于 CHD（n：139）（p<0.001）。
所有家庭治疗模式亚组的 COVID-19 感染率和死亡率均明显低于 CHD。
